A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout

Gout is the most common form of arthritis in adults. It is often associated with other comorbidities, which contraindicate the use of conventional therapies. The discovery of the role of interleukin-1β (IL-1β) in orchestrating the monosodium urate crystal-induced inflammatory response offered new th...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology and therapy. 2018-06, Vol.5 (1), p.303-310
Main Authors: Marotto, Daniela, De Santis, Antonella, Chessa, Donatella, Firinu, Davide, Del Giacco, Stefano
Format: Article
Language:English
Subjects:
Antigens
Arthritis
Blood tests
Cardiac arrhythmia
Cardiomyopathy
Case Report
Clinical outcomes
Contraindications
Cytokines
Drug dosages
Drug therapy
Family Medicine
General Practice
Hepatitis
Hypertension
Internal Medicine
Ischemia
Knee
Medicine
Medicine & Public Health
Monoclonal antibodies
Orthopedics
Patients
Prescription drugs
Quality of Life Research
Rheumatism
Rheumatology
Signal transduction
Steroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gout is the most common form of arthritis in adults. It is often associated with other comorbidities, which contraindicate the use of conventional therapies. The discovery of the role of interleukin-1β (IL-1β) in orchestrating the monosodium urate crystal-induced inflammatory response offered new therapeutic prospects to refractory patients, or to those in whom standard therapies are contraindicated. This paper describes a clinical case of a 65-year-old man with chronic tophaceous gouty arthropathy and subintrant flares, who had comorbidities contraindicating the use of conventional gout therapies—to which he did not respond—who was treated with canakinumab, a monoclonal selective inhibitor of IL-1β. The patient reported a gradual, rapid, and significant reduction in pain, with a response observed within 12 h of the administration of the drug. Consistent with previous clinical studies, canakinumab appeared to be a viable, safe, and effective alternative to conventional therapies in this patient with gout who had limited therapeutic options. Funding: Novartis Farma, Italy
ISSN:2198-6576
2198-6584
DOI:10.1007/s40744-018-0104-8